Drugs / αPD1/CTLA4-MSLN-CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06248697 | Jan 2023 → Jul 2026 overdue | neoplasm | Shanghai Cell Therapy Group Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | αPD1/CTLA4-MSLN-CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06248697 ↗ |
| Known as | BZE2209 | “BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and...” NCT06248697 ↗ |
| Modality | Cell therapy | “autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR)” NCT06248697 ↗ |
| Route | Intravenous | “direct intravenous infusion” NCT06248697 ↗ |
| Target | MSLN | “mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells” NCT06248697 ↗ |